SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer  

作　　者：Shu-Jing Yu Jie-Kai Yu Wei-Ting Ge Han-Guang Hu Ying Yuan Shu Zheng 

机构地区：[1]Department of Radiation Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Science, Zhejiang Province, China), the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310009, Zhejiang Province, China [2]Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Science, Zhejiang Province, China), the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310009, Zhejiang Province, China [3]Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310009, Zhejiang Province, China

出　　处：《World Journal of Gastroenterology》2011年第15期2028-2036,共9页世界胃肠病学杂志（英文版）

基　　金：Supported by Grants from the Major State Basic Research Development Program of China, 973 Program No. 2004CB518707;the Zhejiang Provincial Natural Science Foundation of China,No. R2090353;the Fundamental Research Funds for the Central Universities, No. KYJD09007

摘　　要：AIM: To investigate the expression of markers that are correlated with the prognosis of colorectal cancer (CRC) patients. METHODS: One hundred and fifty-six CRC patientswere followed up for more than 3 years after radical surgery. Immunohistochemical (IHC) analysis was performed to detect the expression of 14 pathway-related markers (p53, APC, p21ras, E-cadherin, endothelin-B receptor, Shp2, ADCY-2, SPARCL1, neuroligin1, hsp27, mmp-9, MAPK, MSH2 and rho) in specimens from these patients. Bioinformatics analysis involving a Support Vector Machine (SVM) was used to determine the best prognostic model from combinations of these markers. RESULTS: Seven markers (SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK) were significantly related to the prognosis and clinical pathological features of the CRC patients (P < 0.05). Prognostic models were established through SVM from combinations of these 7 markers and proved able to differentiate patients with dissimilar survival, especially in stage Ⅱ/Ⅲ patients. According to the best prognostic model, the p53/SPARCL1 model, patients having high p53 and low SPARCL1 expression had about 50% lower 3-year survival than others (P < 0.001). CONCLUSION: SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are potential prognostic markers in CRC. A p53/SPARCL1 bioinformatics model may be used as a supplement to tumor-nodes-metastasis staging.AIM： To investigate the expression of markers that are correlated with the prognosis of colorectal cancer （CRC） patients. METHODS： One hundred and fifty-six CRC patientswere followed up for more than 3 years after radical surgery. Immunohistochemical （IHC） analysis was performed to detect the expression of 14 pathway-related markers （p53, APC, p21ras, E-cadherin, endothelin-B receptor, Shp2, ADCY-2, SPARCL1, neuroligin1, hsp27, mmp-9, MAPK, MSH2 and rho） in specimens from these patients. Bioinformatics analysis involving a Support Vector Machine （SVM） was used to determine the best prognostic model from combinations of these markers. RESULTS： Seven markers （SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK） were significantly related to the prognosis and clinical pathological features of the CRC patients （P 0.05）. Prognostic models were established through SVM from combinations of these 7 markers and proved able to differentiate patients with dissimilar survival, especially in stage Ⅱ/Ⅲ patients. According to the best prognostic model, the p53/SPARCL1 model, patients having high p53 and low SPARCL1 expression had about 50% lower 3-year survival than others （P 0.001）. CONCLUSION： SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are potential prognostic markers in CRC. A p53/SPARCL1 bioinformatics model may be used as a supplement to tumor-nodes-metastasis staging.

关 键 词：Colorectal cancer Prognosis SPARCL1 P53 BIOINFORMATICS 

分 类 号：Q26[生物学—细胞生物学] Q255